- Home
- NFE vs NAMS Comparison
NFE vs NAMS Comparison
Compare NFE & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NFE
- NAMS
- Stock Information
- Founded
- NFE 2014
- NAMS 2019
- Country
- NFE United States
- NAMS Netherlands
- Employees
- NFE N/A
- NAMS N/A
- Industry
- NFE Oil/Gas Transmission
- NAMS Biotechnology: Pharmaceutical Preparations
- Sector
- NFE Utilities
- NAMS Health Care
- Exchange
- NFE Nasdaq
- NAMS Nasdaq
- Market Cap
- NFE 2.4B
- NAMS 1.9B
- IPO Year
- NFE 2019
- NAMS N/A
- Fundamental
- Price
- NFE $9.75
- NAMS $20.20
- Analyst Decision
- NFE Buy
- NAMS Strong Buy
- Analyst Count
- NFE 6
- NAMS 6
- Target Price
- NFE $22.00
- NAMS $33.80
- AVG Volume (30 Days)
- NFE 5.4M
- NAMS 722.3K
- Earning Date
- NFE 11-07-2024
- NAMS 11-06-2024
- Dividend Yield
- NFE 4.10%
- NAMS N/A
- EPS Growth
- NFE N/A
- NAMS N/A
- EPS
- NFE 0.91
- NAMS N/A
- Revenue
- NFE $2,417,879,000.00
- NAMS $33,594,000.00
- Revenue This Year
- NFE N/A
- NAMS N/A
- Revenue Next Year
- NFE $31.74
- NAMS N/A
- P/E Ratio
- NFE $10.77
- NAMS N/A
- Revenue Growth
- NFE 11.48
- NAMS 78.77
- 52 Week Low
- NFE $7.82
- NAMS $8.90
- 52 Week High
- NFE $40.04
- NAMS $26.35
- Technical
- Relative Strength Index (RSI)
- NFE 55.88
- NAMS 45.06
- Support Level
- NFE $8.41
- NAMS $19.59
- Resistance Level
- NFE $9.84
- NAMS $25.32
- Average True Range (ATR)
- NFE 0.71
- NAMS 1.40
- MACD
- NFE 0.12
- NAMS -0.46
- Stochastic Oscillator
- NFE 81.32
- NAMS 33.59
About NFE New Fortress Energy Inc.
New Fortress Energy is an integrated gas-to-power company. Its business model spans the entire production and delivery chain from natural gas procurement and liquefaction to logistics, shipping, terminals, and conversion or development of a natural gas-fired generation. It has invested in floating, liquefied natural gas vessels to both lower the cost of acquiring gas while securing a long-term supply for its terminals. Its segments include terminals and infrastructure, or T&I, and ships.
About NAMS NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.